About Cassiopea
Cassiopea is a company based in Lainate (Italy) founded in 2009 was acquired by Cosmo Pharmaceuticals in October 2021. The company has 653 employees as of April 06, 2024. Cassiopea operates in a competitive market with competitors including Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
- Headquarter Lainate, Italy
- Employees 653 as on 06 Apr, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Jurisdiction Shaikpet, Telangana, India
-
Annual Revenue
$41.42 M (USD)59.42as on Mar 31, 2023
-
Net Profit
$6.79 M (USD)281.61as on Mar 31, 2023
-
EBITDA
$10.42 M (USD)246.16as on Mar 31, 2023
-
Latest Funding Round
Not available
- Investors
-
Employee Count
653
as on Apr 06, 2024
-
Acquired by
Cosmo Pharmaceuticals
(Oct 04, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cassiopea
Detailed funding history for Cassiopea
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Cassiopea
Cassiopea has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cosmo Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for gastrointestinal diseases are developed and provided.
|
Locked | Locked | Locked |
Investor details for Cassiopea
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cassiopea
Investment portfolio details for Cassiopea
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cassiopea
Detailed financials for Cassiopea
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cassiopea Comparisons
Peer comparison for Cassiopea
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cassiopea
Cassiopea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Skin care products are developed and manufactured by SkinMedica.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
|
| Locked | Locked | Locked |
Solutions for dermatological therapeutics and consumer products are provided.
|
Detailed competitors of Cassiopea
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cassiopea
Complete news archive for Cassiopea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cassiopea
Cassiopea was founded in 2009.
Cassiopea is headquartered in Lainate, Italy. It is registered at Lainate, Lombardy, Italy.
As of Apr 06, 2024, the latest employee count at Cassiopea is 653.
Annual revenue of Cassiopea is $41.42M as on Mar 31, 2023.
Cassiopea, founded in 2009 and based in Lainate, Italy, operates as a clinical-stage pharmaceutical company specializing in dermatology. Topical treatments for acne, androgenic alopecia, and genital warts are targeted through four drug candidates: Winlevi in Phase III for acne, Breezula in Phase II for alopecia, another for acne in Phase II, and one for HPV in Phase I. The company was renamed from Cosmo Dermatos in April 2015.
Cassiopea's top competitors include Revance Therapeutics, Dermavant and Collplant.
Cassiopea has 1 investor. Key investors include Cosmo Pharmaceuticals.